Tag: Insulet
ResMed, AdaptHealth make tech listÂ
January 26, 2023HME News Staff
YARMOUTH, Maine – Several HME companies have made the Power 500 Technology Companies list, a nod to their commitment to improving the health of people around the world. In the Medical Devices category, ResMed, Dexcom, Insulet Corp., AdaptHealth and Masimo were all listed as leaders. The list includes companies that demonstrate product or service leadership, technical depth in their specific fields, consistent organizational growth or evolution, operational excellence and high-caliber management...
Insulet’s Omnipod 5 cleared for use ages two and up
August 24, 2022HME News Staff
ACTON, Mass. – Insulet has received U.S. Food and Drug Administration clearance for its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with Type 1 diabetes. “We received tremendous first-hand reports of how Omnipod 5 made diabetes management easier for our pivotal trial participants, and the clinical data demonstrated impressive glycemic improvements, as well,” said Dr. Trang Ly, MBBS, FRACP, PhD, Insulet’s senior vice president and medical...
Earnings roundup: Great Elm, InfuSystem, InsuletÂ
May 9, 2022HME News Staff
WALTHAM, Mass. – Great Elm Group’s DME division grew total revenue by 19.2% to $15.6 million in the third quarter of fiscal year 2022, driven by strong resupply sales. The increase in revenue was primarily attributable to contributions from the previous acquisitions of AMPM in March 2021 and MedOne in August 2021. “Our investment in DME continues to perform well, despite challenging supply chain conditions,” said Peter Reed, CEO of Great Elm. The DME division reported a net...
In brief: Invacare layoffs, Philips recall, ResMed exec
May 6, 2022HME News Staff
ELYRIA, Ohio – Invacare is streamlining its operations in the United States, primarily related to headcount reductions, to improve its cost structure, according to a May 4 filing with the U.S. Securities and Exchange Commission.
As a result, the company anticipates annual pre-tax savings of about $2.8 million, with about $1.9 million to be realized in 2022. It will incur restructuring charges of $800,000 and expects to make cash payments in the same amount, primarily related to...
In brief: Inogen revenues, UnitedHealth merger, Heartland registration
February 25, 2022HME News Staff
GOLETA, Calif. – Inogen reported revenue of $76.4 million for the fourth quarter of 2021, an increase of 3.3% over the same period in 2020, driven by a 23.3% in domestic direct-to-consumer sales to $33 million.
Domestic business-to-business sales in the fourth quarter of 2021 decreased 57.6% to $10.3 million compared to $24.2 million in the fourth quarter of 2020, primarily due to the supply chain constraints that limited product availability in this channel.
Rental revenue...
Insulet surpasses $1 billion in Omnipod revenue
February 25, 2022HME News Staff
ACTON, Mass. – Insulet Corporation reported revenue of $307.7 million for the fourth quarter of 2021, and full year revenue of $1.1 billion. Total Omnipod revenue was $275.8 million for the quarter and $1 billion for the full year. Of that, U.S. Omnipod revenue for the year was $651.5 million and international Omnipod revenue of $359.9 million. “2021 was another successful year for Insulet, as we reached an important milestone of over $1 billion in revenue and advanced our strategic priorities,”...
In brief: Woman of the Year finalists, supply chain relief, Quipt’s acquisition
November 12, 2021HME News Staff
WATERLOO, Iowa – The finalists for this year’s HME Woman of the Year are Trisha Bailey, CEO of Medical Hotspots/Bailey’s Medical; Neidi Mack, vice president for ancillary services at Prism Health Care Services/The Alden Network; Katie Stevens, CEO at Reliable Medical Supply; and Victoria Peterson, administrator at RespMed. “These HME Woman of the Year finalists are leaders in their companies and communities,” said Clint Geffert, president of VGM & Associates. “They...
Insulet highlights ‘growing power’ of Omnipod
November 8, 2021HME News Staff
ACTON, Mass. – Insulet Corp. reported revenue of $275.6 million for the third quarter of 2021, up 17.8% over the same period last year.
It reported revenue was $260.3 million, up 22.7%, for Omnipod.
"Our third quarter results reflect the growing power of Omnipod,” said Shacey Petrovic, president and CEO. “We are driving global new customer starts, have momentum across our business, and are advancing exciting new innovations. We continue to share compelling clinical...
Insulet celebrates Diabetes Awareness month
November 4, 2021HME News Staff
ACTON, Mass. – Insulet, maker of the Omnipod, will virtually ring the closing bell at the Nasdaq Stock Market on Nov. 15, as part of its planned activities to recognize Diabetes Awareness Month and World Diabetes Day during the month of November. “We are passionate about improving the lives of people with diabetes and at Insulet we strive to make Pod therapy universally accessible to anyone requiring daily insulin,” said Shacey Petrovic, president and CEO. “With over 400 million...
Insulet posts Q4 revenue increase, net loss
February 24, 2021HME News Staff
ACTON, Mass. – Insulet reported revenues of $246.1 million for the fourth quarter of 2020, an increase of 17.5% over the same quarter in 2019. Full-year revenues were $904.4 million, an increase of 22.5% compared to the previous year. For the quarter, U.S. Omnipod revenue was $231.1 million and International Omnipod revenue was $149.2 million. Omnipod revenue for the full year was $834.9 million: $526.9 million in U.S. Omnipod...